JP2014519522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519522A5 JP2014519522A5 JP2014515224A JP2014515224A JP2014519522A5 JP 2014519522 A5 JP2014519522 A5 JP 2014519522A5 JP 2014515224 A JP2014515224 A JP 2014515224A JP 2014515224 A JP2014515224 A JP 2014515224A JP 2014519522 A5 JP2014519522 A5 JP 2014519522A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid residues
- antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000539 amino acid group Chemical group 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 101150070527 CRD1 gene Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 claims 4
- 206010051728 Bone erosion Diseases 0.000 claims 3
- 210000000845 cartilage Anatomy 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000002997 osteoclast Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002437 synoviocyte Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11170402.9 | 2011-06-17 | ||
| EP11170402 | 2011-06-17 | ||
| US201161501533P | 2011-06-27 | 2011-06-27 | |
| US61/501,533 | 2011-06-27 | ||
| PCT/EP2012/061583 WO2012172102A1 (en) | 2011-06-17 | 2012-06-18 | Selective elimination of erosive cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519522A JP2014519522A (ja) | 2014-08-14 |
| JP2014519522A5 true JP2014519522A5 (enExample) | 2015-08-06 |
| JP6334395B2 JP6334395B2 (ja) | 2018-05-30 |
Family
ID=44904625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014515224A Active JP6334395B2 (ja) | 2011-06-17 | 2012-06-18 | 侵食細胞の選択的排除 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9512228B2 (enExample) |
| EP (1) | EP2721068B1 (enExample) |
| JP (1) | JP6334395B2 (enExample) |
| KR (1) | KR102047248B1 (enExample) |
| CN (1) | CN103635487B (enExample) |
| AU (1) | AU2012268939B2 (enExample) |
| BR (1) | BR112013032217B1 (enExample) |
| CA (1) | CA2838220C (enExample) |
| MX (1) | MX342131B (enExample) |
| RU (1) | RU2617056C2 (enExample) |
| WO (1) | WO2012172102A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3026063A1 (en) | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| CN103635487B (zh) | 2011-06-17 | 2016-10-12 | 诺沃—诺迪斯克有限公司 | 选择性消除侵蚀性细胞 |
| SG11201701387SA (en) | 2014-09-16 | 2017-03-30 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
| EP4368205A1 (en) | 2014-09-16 | 2024-05-15 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| WO2016062851A1 (en) * | 2014-10-23 | 2016-04-28 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| SI3405495T1 (sl) | 2016-01-21 | 2021-08-31 | Innate Pharma | Nevtralizacija inhibitornih poti v limfocitih |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| WO2019175182A1 (en) | 2018-03-13 | 2019-09-19 | Innate Pharma | Treatment of head and neck cancer |
| EP3793607A1 (en) | 2018-05-15 | 2021-03-24 | MedImmune Limited | Treatment of cancer |
| WO2020205440A1 (en) * | 2019-03-29 | 2020-10-08 | Dren Bio, Inc. | Methods of reducing large granular lymphocyte and natural killer cell levels |
| CA3181963A1 (en) * | 2020-05-04 | 2021-11-11 | Immunorizon Ltd. | Precursor tri-specific antibody constructs and methods of use thereof |
| EP4221752A4 (en) | 2020-09-30 | 2024-12-04 | Dren Bio, Inc. | ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF |
| CN114524876B (zh) * | 2020-11-23 | 2025-12-05 | 南京北恒生物科技有限公司 | 靶向nkg2a的抗体及其用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| JPH03112486A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞 |
| JPH03112485A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞 |
| JPH03112487A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞 |
| JPH03112484A (ja) | 1989-09-26 | 1991-05-14 | Nisshin Seito Kk | 新規制限酵素及びその製造方法 |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JPH03112484U (enExample) | 1990-03-02 | 1991-11-18 | ||
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5489525A (en) | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
| EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| EP1266014A2 (en) | 2000-03-24 | 2002-12-18 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| US6999941B1 (en) | 2000-07-11 | 2006-02-14 | Amazon.Com, Inc. | Providing gift clustering functionality to assist a user in ordering multiple items for a recipient |
| JP2004528824A (ja) | 2000-12-18 | 2004-09-24 | アーンスティテュ ナシオナール ド ラ サント エ ド ラ ルシェルシェ メディカル（イー．エンヌ．エス．ウー．エール．エンム．） | 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の新規な診断及び治療法 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030095965A1 (en) | 2001-05-02 | 2003-05-22 | Katrien Van Beneden | Antibodies to Ly49E and CD94/NKG2 receptors |
| AU2002325333B2 (en) | 2001-07-19 | 2008-04-03 | Innate Pharma | NTB-A, a surface molecule involved in natural killer cells activity |
| WO2003011895A2 (en) | 2001-07-31 | 2003-02-13 | Soederstroem Karl Petter | Compositions and methods for modulation of immune responses |
| WO2003095965A2 (en) | 2002-05-13 | 2003-11-20 | Envirotech Products Limited | Tank valve testing method |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| CN1751236A (zh) | 2002-12-16 | 2006-03-22 | 健泰科生物技术公司 | 表达人cd20的转基因小鼠 |
| PT1648507T (pt) | 2003-07-24 | 2017-03-20 | Innate Pharma Sa | Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk |
| JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用 |
| WO2005105849A1 (en) | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for treating proliferative disorders such as nk-type ldgl |
| ES2526343T3 (es) * | 2004-06-03 | 2015-01-09 | Novimmune Sa | Anticuerpos anti-CD3 y métodos de uso de los mismos |
| CN101107269B (zh) * | 2004-12-28 | 2012-10-31 | 依奈特制药公司 | 抗nkg2a的单克隆抗体 |
| EP3026063A1 (en) | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| CA2623109C (en) * | 2005-10-14 | 2019-02-19 | Innate Pharma | Nk cell-depleting antibodies for treating immunoproliferative disorders |
| MX2008015830A (es) | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| MX2010007935A (es) | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| CN103635487B (zh) * | 2011-06-17 | 2016-10-12 | 诺沃—诺迪斯克有限公司 | 选择性消除侵蚀性细胞 |
| AU2015307316A1 (en) | 2014-08-28 | 2017-03-09 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | CD94/NKG2A and/or CD94/NKG2B antibody, vaccine combinations |
| SG11201701387SA (en) | 2014-09-16 | 2017-03-30 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
| EP4368205A1 (en) | 2014-09-16 | 2024-05-15 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| WO2016062851A1 (en) | 2014-10-23 | 2016-04-28 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| SI3405495T1 (sl) | 2016-01-21 | 2021-08-31 | Innate Pharma | Nevtralizacija inhibitornih poti v limfocitih |
-
2012
- 2012-06-18 CN CN201280029746.4A patent/CN103635487B/zh active Active
- 2012-06-18 US US14/124,876 patent/US9512228B2/en active Active
- 2012-06-18 RU RU2013158625A patent/RU2617056C2/ru active
- 2012-06-18 BR BR112013032217-9A patent/BR112013032217B1/pt active IP Right Grant
- 2012-06-18 EP EP12729529.3A patent/EP2721068B1/en active Active
- 2012-06-18 MX MX2013014203A patent/MX342131B/es active IP Right Grant
- 2012-06-18 CA CA2838220A patent/CA2838220C/en active Active
- 2012-06-18 AU AU2012268939A patent/AU2012268939B2/en active Active
- 2012-06-18 WO PCT/EP2012/061583 patent/WO2012172102A1/en not_active Ceased
- 2012-06-18 JP JP2014515224A patent/JP6334395B2/ja active Active
- 2012-06-18 KR KR1020147000532A patent/KR102047248B1/ko active Active
-
2016
- 2016-11-18 US US15/355,087 patent/US20170073417A1/en not_active Abandoned
-
2019
- 2019-12-18 US US16/718,935 patent/US11697687B2/en active Active
-
2023
- 2023-05-23 US US18/321,810 patent/US20230416374A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519522A5 (enExample) | ||
| RU2013158625A (ru) | Селективная элиминация эрозийных клеток | |
| FI3922645T3 (fi) | Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja | |
| JP2015508762A5 (enExample) | ||
| JP2012021001A5 (enExample) | ||
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| JP2014169326A5 (enExample) | ||
| JP2018521691A5 (enExample) | ||
| HRP20171585T1 (hr) | Antitijela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloičnim stanicama 1 (trem-1) | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| JP2014524748A5 (enExample) | ||
| HRP20140604T1 (hr) | Sredstva koja djeluju na cd138 i njihova upotreba | |
| RU2017105120A (ru) | Cd3-связывающий домен | |
| RU2013110874A (ru) | Антитела против il-18r1 и их применения | |
| FI2691417T4 (fi) | Vasta-aineen Fc-variantteja | |
| RU2012128651A (ru) | Антитела, связывающиеся преимущественно с внеклеточным доменом 4 человеческого csf-1r, и их применение | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| IL299282A (en) | Enhanced variable complexes of immunoglobulins | |
| RU2011101969A (ru) | Антитела к человеческому интерлейкину-20 | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| RU2012129735A (ru) | Антитела к her3 и их применения | |
| RU2012156938A (ru) | Антитела против gdf8 человека |